Adendra CEO Raj Mehta and scientific co-founder Caetano Reis e Sousa

Ap­ple Tree Part­ners leaps across the pond to launch a UK biotech look­ing to crack the se­crets of den­drit­ic cells

Once large­ly a mys­tery to re­searchers, the far-flung realm of cells in the im­mune sys­tem has emerged as a fruit­ful sand­box for drug de­vel­op­ers. A new UK biotech is lean­ing on re­search in­to the grow­ing role of den­drit­ic cells in spurring im­mune re­spons­es, and US ven­ture firm Ap­ple Tree Part­ners is bankrolling its ear­ly ef­forts.

Lon­don-based Aden­dra Ther­a­peu­tics launched Tues­day with $53 mil­lion from found­ing in­vestor ATP and re­search out of the Fran­cis Crick In­sti­tute look­ing to lever­age new in­sights in­to how den­drit­ic cells sic preda­to­ry T cells on­to tu­mors — and their role in dri­ving au­toim­mune dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.